Shots:

• The approval is based on a study supporting its safety- efficacy in dogs with a measurable cutaneous/ SC MCT on the lower leg and follows the EMA’s MAA granted in early 2020
• Stelfonta provides 75% complete tumor resolution after just one injection- and dogs quickly regain pre-treatment QoL. The therapy will be launched in the US in the coming months and then made available to primary care veterinarians from early 2021
• QBiotics is currently investigating Stelfonta in a series of human P-I & P-II clinical trials targeting solid tumors as both as monothx. and an immune checkpoint inhibitor combination therapy

­ Ref: QBiotics | Image: iStock